SAB Biotherapeutics, Inc.
$3.85
Mkt Cap 36.8M
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious dis…
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials. The company was founded in 2014 and is headquartered in Miami Beach, Florida.
—
/100 Overall
Calculating score…
Running full analysis
Ready to value this company?
Run a full DCF model with Monte Carlo simulation.
Run DCF Valuation →
Run a full DCF model with Monte Carlo simulation.
Key Metrics
Loading full analysis…
Running full 6-factor analysis…